In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medical Device and In Vitro Diagnostics/Research Deals Statistics Quarterly, Q1 2011

Executive Summary

For the first three months of 2011, medical device companies raised $733 million, with venture rounds bringing in $494 million. Two-thirds of the $3.9 billion in M&A activity came from Terumo's monstrous $2.6 billion cash takeover of US blood processing equipment maker CaridianBCT Holding. Buoyed by Opko Health's $105 million follow-on, the FOPO category represented almost half of the first quarter's in vitro diagnostics/research $370 million total. The stand-out IVD acquisition was Danaher's $6.8 billion takeover of publicly traded Beckman Coulter.

You may also be interested in...

Quest Highlights Diagnostics Pipeline As Key Component Of Celera Purchase

Quest Diagnostics will expand its molecular diagnostic product offerings and gain a substantial biomarker R&D pipeline while boosting its cardiovascular testing services business through the purchase of Celera for $344 million in cash.

Terumo Will Top Blood Transfusion Device Space With $2.6 Billion Acquisition

Diversified Japanese device maker Terumo will become the global leader in the blood transfusion product market with its planned $2.6 billion acquisition of privately owned CaridianBCT.

Accuray Buys TomoTherapy To Create 'Premier' Radiation Oncology Company

Radiosurgery device maker Accuray is acquiring radiation therapy developer TomoTherapy for $277 million in cash and stock to form “the premier radiation oncology company,” according to the firms.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts